The prevalence of PIK3CA mutations in gastric and colon cancer - PubMed (original) (raw)
The prevalence of PIK3CA mutations in gastric and colon cancer
Sérgia Velho et al. Eur J Cancer. 2005 Jul.
Abstract
A wide variety of tumours show PIK3CA mutations leading to increased phosphatidylinositol-3 kinase (PI3K) activity. We have determined the frequency of PIK3CA mutations in exons 9 and 20 that has previously been reported as mutational hotspot regions in distinct tumour models. One hundred and fifty gastrointestinal carcinomas (47 gastric and 103 colorectal) that were characterised for MSI status (76 MSI and 74 MSS) by PCR-SSCP sequencing were evaluated. We also analysed the association between PIK3CA mutations and KRAS or BRAF mutations. PIK3CA mutations in exons 9 and 20 were present in 13.6% and 10.6% of colorectal and gastric carcinomas, respectively. No differences in frequency and type of PIK3CA mutations were found between MSI and MSS colorectal carcinomas. All gastric carcinomas with PIK3CA mutations were MSI. The number of cases harbouring concomitant PIK3CA and KRAS or BRAF mutations was higher in colorectal than in gastric carcinomas (P = 0.016). In colorectal carcinoma, PIK3CA mutations occur preferentially together with activating KRAS-BRAF mutations (MSI and MSS) while in gastric carcinomas PIK3CA mutations tend to occur as isolated events (MSI).
Similar articles
- Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C, Velho S, Domingo E, Preto A, Hofstra RM, Hamelin R, Yamamoto H, Seruca R, Schwartz S Jr. Oliveira C, et al. Oncogene. 2005 Nov 17;24(51):7630-4. doi: 10.1038/sj.onc.1208906. Oncogene. 2005. PMID: 16007118 - Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y. Sukawa Y, et al. World J Gastroenterol. 2012 Dec 7;18(45):6577-86. doi: 10.3748/wjg.v18.i45.6577. World J Gastroenterol. 2012. PMID: 23236232 Free PMC article. - The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, Bardelli A, Scarpa A. Barbi S, et al. J Exp Clin Cancer Res. 2010 Apr 16;29(1):32. doi: 10.1186/1756-9966-29-32. J Exp Clin Cancer Res. 2010. PMID: 20398348 Free PMC article. - PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM. Day FL, et al. Clin Cancer Res. 2013 Jun 15;19(12):3285-96. doi: 10.1158/1078-0432.CCR-12-3614. Epub 2013 Apr 30. Clin Cancer Res. 2013. PMID: 23633456 - The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. Therkildsen C, et al. Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Acta Oncol. 2014. PMID: 24666267 Review.
Cited by
- Molecular mechanisms of chemoresistance in gastric cancer.
Shi WJ, Gao JB. Shi WJ, et al. World J Gastrointest Oncol. 2016 Sep 15;8(9):673-81. doi: 10.4251/wjgo.v8.i9.673. World J Gastrointest Oncol. 2016. PMID: 27672425 Free PMC article. Review. - Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.
Sunakawa Y, Lenz HJ. Sunakawa Y, et al. Curr Treat Options Oncol. 2015 Apr;16(4):17. doi: 10.1007/s11864-015-0331-y. Curr Treat Options Oncol. 2015. PMID: 25813036 Review. - Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, Lee JL, Chang HM, Kim TW, Kang YK. Yoon DH, et al. Br J Cancer. 2012 Mar 13;106(6):1039-44. doi: 10.1038/bjc.2012.47. Epub 2012 Feb 16. Br J Cancer. 2012. PMID: 22343617 Free PMC article. Clinical Trial. - PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population.
Herreros-Villanueva M, Gomez-Manero N, Muñiz P, García-Girón C, Coma del Corral MJ. Herreros-Villanueva M, et al. Mol Biol Rep. 2011 Feb;38(2):1347-51. doi: 10.1007/s11033-010-0236-6. Epub 2010 Jun 23. Mol Biol Rep. 2011. PMID: 20571907 - A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors.
Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S. Fukamachi H, et al. J Exp Clin Cancer Res. 2019 Mar 12;38(1):127. doi: 10.1186/s13046-019-1121-3. J Exp Clin Cancer Res. 2019. PMID: 30866995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous